At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 23 enrolled
Drug / intervention
BKM120 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib Study of BKM120 With Weekly Cisplatin and Radiotherapy in High Risk Locally Advanced Squamous Cell Cancer of the Head and Neck
In Brief
A Phase 1 clinical trial evaluating BKM120, Cisplatin, and 1 other intervention for Carcinoma, Squamous Cell of Head and Neck and 5 related conditions. Completed, enrolled 23 participants across 1 site.
Detailed Summary
This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Early Invasive Cervical Squamous Cell Carcinoma, Carcinoma of Larynx, Cancer of Nasopharynx
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartSep 2014
Primary CompletionDec 2019
Study CompletionJan 2022
TodayJul 2026
First PostedApr 15, 2014
Enrollment StartSep 29, 2014
Primary CompletionDec 6, 2019
Study CompletionJan 1, 2022
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 12.2 years ago
Interventions
BKM120drug
BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
Cisplatindrug
Cisplatin is a chemotherapy drug
Intensity-modulated radiotherapy (IMRT)radiation
IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells